CH EPL (R5)
0.1.0 - ci-build
CH EPL (R5), published by Federal Office of Public Health FOPH. This guide is not an authorized publication; it is the continuous build for version 0.1.0 built by the FHIR (HL7® FHIR® Standard) CI Build. This version is based on the current content of https://github.com/bag-epl/bag-epl-fhir/ and changes regularly. See the Directory of published versions
Generated Narrative: Bundle b2eb19be-cca4-4fd8-a2a3-84d05631e6c0
Bundle b2eb19be-cca4-4fd8-a2a3-84d05631e6c0 of type collection
Entry 1 - fullUrl = http://example.org/MedicinalProductDefinition/Keytruda-100mg-Vial
Resource MedicinalProductDefinition:
Generated Narrative: MedicinalProductDefinition Keytruda-100mg-Vial
CH - SMC Authorized Dose Form: Concentrate for solution for infusion
CH - EPL Full Limitation Text: Lokal rezidiverendes, nicht resezierbares oder metastasiertes triple-negatives Mammakarzinom (in Kombination mit Chemotherapie) KN 355 (mit Preismodell). KEYTRUDA in Kombination mit Chemotherapie zur Behandlung des lokal rezidivierenden, nicht resezierbaren oder metastasierten triple-negativen Mammakarzinoms bei Erwachsenen, deren Tumore PD-L1 mit einem CPS ≥10 exprimieren und die keine vorherige Chemotherapie bei metastasierter Erkrankung erhalten haben. - Falls Patienten vorhergehend systemisch im (neo)adjuvanten Setting behandelt wurden: Mit Vortherapie auf Antrazyklin-Basis, ausser diese war kontraindiziert. - Ohne Therapie mit Checkpoint-Inhibitoren innerhalb der letzten 12 Monate. Folgender Code ist an den Krankenversicherer zu übermitteln: 20416.17
identifier:
http://SMC.ch/ig/idmp/NamingSystem/IDSystem-ch-MPID
/CH-7601001001138-6623101domain: Human
indication:
xxxxxxx
legalStatusOfSupply: One-time dispensation on medical or veterinary prescription (A)
classification: norethisterone and estrogen, Biotechnologika
attachedDocument: DocumentReference: status = current; type = Fachinformation
name
productName: KEYTRUDA Inf Konz 100 mg/4ml
type: Swissmedic
Usages
Country Language Switzerland German (Switzerland)
Entry 2 - fullUrl = http://example.org/DocumentReference/DocRef-FI-Keytruda
Resource DocumentReference:
Generated Narrative: DocumentReference DocRef-FI-Keytruda
status: Current
type: Fachinformation
content
Attachments
Url https://swissmedicinfo.ch/showTextAccepted.aspx?textType=FI&lang=DE&authNr=66231&supportMultipleResults=1
Entry 3 - fullUrl = http://example.org/RegulatedAuthorisation/MA-6623101
Resource RegulatedAuthorization:
Generated Narrative: RegulatedAuthorization MA-6623101
identifier:
http://SMC.ch/ig/idmp/NamingSystem/IDSystem-ch-MarketingAuthorisationNumber
/6623101type: Marketing Authorisation
region: Switzerland
status: zugelassen
statusDate: 2022-02-17
holder: Organization MSD Merck Sharp & Dohme AG
regulator: Organization SMC
Generated Narrative: Organization #holder-MSD-Merck-Sharp-Dohme-AG
identifier:
urn:oid:1.2.276.0.76
/100080484, GLN/7601001001138name: MSD Merck Sharp & Dohme AG
Generated Narrative: Organization #regulator-SMC
identifier:
urn:oid:1.2.276.0.76
/100010911, GLN/7601001398511name: SMC
Entry 4 - fullUrl = http://example.org/PackagedProductDefinition/PMP-Keytruda-100mg-4ml-Solution-for-Infusion
Resource PackagedProductDefinition:
Generated Narrative: PackagedProductDefinition PMP-Keytruda-100mg-4ml-Solution-for-Infusion
identifier:
http://SMC.ch/ig/idmp/NamingSystem/IDSystem-ch-PCID
/CH-7601001001138-6623101-001description:
KEYTRUDA Inf Konz 100 mg/4ml Durchstf
LegalStatusOfSupplies
Code One-time dispensation on medical or veterinary prescription (A) packaging
identifier:
urn:oid:2.51.1.1
/7680662310018type: Box
quantity: 1
ShelfLifeStorages
Type SpecialPrecautionsForStorage Shelf life of the medicinal product as packaged for sale Im Kühlschrank (2°C - 8°C) vor Licht Schützen Nicht einfrieren In der Originalverpackung aufbewahren.
Entry 5 - fullUrl = http://example.org/RegulatedAuthorisation/MA-66231001
Resource RegulatedAuthorization:
Generated Narrative: RegulatedAuthorization MA-66231001
identifier:
http://SMC.ch/ig/idmp/NamingSystem/IDSystem-ch-MarketingAuthorisationNumber
/66231001type: Marketing Authorisation
region: Switzerland
status: zugelassen
statusDate: 2022-02-17
holder: Organization MSD Merck Sharp & Dohme AG
regulator: Organization SMC
Generated Narrative: Organization #holder-MSD-Merck-Sharp-Dohme-AG
identifier:
urn:oid:1.2.276.0.76
/100080484, GLN/7601001001138name: MSD Merck Sharp & Dohme AG
Generated Narrative: Organization #regulator-SMC
identifier:
urn:oid:1.2.276.0.76
/100010911, GLN/7601001398511name: SMC
Entry 6 - fullUrl = http://example.org/RegulatedAuthorisation/FOPH-20416
Resource RegulatedAuthorization:
Generated Narrative: RegulatedAuthorization FOPH-20416
CH - EPL Reimbursement SL
- FOPHDossierNumber:
urn:oid:2.16.756.1
/20416- status: Reimbursed
- statusDate: 2023-01-01
- expiryDate: 2025-03-31
- listingStatus: Listed
- listingPeriod: 2023-01-01 --> 2024-12-31
- firstListingDate: 2017-09-01
- costShare: 10
- gamme: Parenteral Depot
CH - EPL Product Price
- value: CHF4,407.68 (CHF)
- type: Ex-factory price
- changeType: Normal price mutation
- changeDate: 2023-01-01
CH - EPL Product Price
- value: CHF4,768.50 (CHF)
- type: Retail price
- changeType: VAT-change
- changeDate: 2024-01-01
type: Reimbursement SL
Indications
Extension Reference ClinicalUseDefinition: type = indication holder: Organization MSD Merck Sharp & Dohme AG
Generated Narrative: Organization #holder-MSD-Merck-Sharp-Dohme-AG
identifier:
urn:oid:1.2.276.0.76
/100080484, GLN/7601001001138name: MSD Merck Sharp & Dohme AG
Entry 7 - fullUrl = http://example.org/ManufacturedItemDefinition/MI-Pembrolizumab-100mg-Vial
Resource ManufacturedItemDefinition:
Generated Narrative: ManufacturedItemDefinition MI-Pembrolizumab-100mg-Vial
status: Active
manufacturedDoseForm: Film-coated tablet
unitOfPresentation: Vial
Entry 8 - fullUrl = http://example.org/AdministrableProductDefinition/PhP-Pembrolizumab-100mg-Vial
Resource AdministrableProductDefinition:
Generated Narrative: AdministrableProductDefinition PhP-Pembrolizumab-100mg-Vial
status: Active
administrableDoseForm: Solution for infusion
unitOfPresentation: Vial
RouteOfAdministrations
Code Intravenous use
Entry 9 - fullUrl = http://example.org/Ingredient/Pembrolizumab100
Resource Ingredient:
Generated Narrative: Ingredient Pembrolizumab100
status: Active
for:
- AdministrableProductDefinition: status = active; administrableDoseForm = Solution for infusion; unitOfPresentation = Vial
- ManufacturedItemDefinition: status = active; manufacturedDoseForm = Film-coated tablet; unitOfPresentation = Vial
role: Wirkstoff
substance
Codes
Concept Pembrolizumab Strengths
Presentation[x] 100 mg (Details: UCUM codemg = 'mg')/1 Vial (Details: EDQM - Standard Terms code15060000 = 'Vial')
Entry 10 - fullUrl = http://example.org/ClinicalUseDefinition/IND-10027400
Resource ClinicalUseDefinition:
Generated Narrative: ClinicalUseDefinition IND-10027400
type: Indication
indication
DiseaseSymptomProcedures
Concept Melanom IntendedEffects
Concept therapeutic
Entry 11 - fullUrl = http://example.org/ClinicalUseDefinition/IND-10075566
Resource ClinicalUseDefinition:
Generated Narrative: ClinicalUseDefinition IND-10075566
type: Indication
indication
DiseaseSymptomProcedures
Concept Triple negative breast cancer IntendedEffects
Concept therapeutic
Entry 12 - fullUrl = http://example.org/ClinicalUseDefinition/IND-10028881
Resource ClinicalUseDefinition:
Generated Narrative: ClinicalUseDefinition IND-10028881
type: Indication
indication
DiseaseSymptomProcedures
Concept Nicht-kleinzelliges Lungenkarzinom IntendedEffects
Concept therapeutic
Entry 13 - fullUrl = http://example.org/ClinicalUseDefinition/IND-10021782
Resource ClinicalUseDefinition:
Generated Narrative: ClinicalUseDefinition IND-10021782
type: Indication
indication
DiseaseSymptomProcedures
Concept Kopf- und Halskarzinom IntendedEffects
Concept therapeutic
Entry 14 - fullUrl = http://example.org/ClinicalUseDefinition/IND-10019927
Resource ClinicalUseDefinition:
Generated Narrative: ClinicalUseDefinition IND-10019927
type: Indication
indication
DiseaseSymptomProcedures
Concept Klassisches Hodgkin Lymphom IntendedEffects
Concept therapeutic
Entry 15 - fullUrl = http://example.org/ClinicalUseDefinition/IND-10043971
Resource ClinicalUseDefinition:
Generated Narrative: ClinicalUseDefinition IND-10043971
type: Indication
indication
DiseaseSymptomProcedures
Concept Primäres mediastinales grosszelliges B-Zell-Lymphom IntendedEffects
Concept therapeutic
Entry 16 - fullUrl = http://example.org/ClinicalUseDefinition/LIM-254837009
Resource ClinicalUseDefinition:
Generated Narrative: ClinicalUseDefinition LIM-254837009
type: Indication
indication
DiseaseSymptomProcedures
Concept Malignant tumor of breast IntendedEffects
Concept therapeutic